Induction of endometrial mesenchymal stem cells into tissue-forming cells suitable for fascial repair

Acta Biomaterialia

Volumn 10, Issue 12, 2014, Pages 5012-5020

  Su, Kai ^a   Edwards, Sharon L ^a   Tan, Ker S ^b   White, Jacinta F ^a   Kandel, Shital ^a   Ramshaw, John A M ^a   Gargett, Caroline E ^b   Werkmeister, Jerome A ^a  

^a CSIRO   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Endometrial mesenchymal stem cells; Gelatin; Pelvic organ prolapse; Polyamide; Tissue engineering

Indexed keywords

BIOCOMPATIBILITY; CELL ENGINEERING; COLLAGEN; DEGRADATION; FIBROBLASTS; GELATION; MUSCLE; SCAFFOLDS (BIOLOGY); STEM CELLS;

'CURRENT; ENDOMETRIAL MESENCHYMAL STEM CELL; GELATIN; MESENCHYMAL STEM CELL; PELVIC ORGAN PROLAPSE; RECONSTRUCTIVE SURGERY; REOPERATION; SMOOTH MUSCLE CELLS; SMOOTH MUSCLES; TISSUES ENGINEERINGS;

CELL CULTURE;

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; GELATIN; GLUTARALDEHYDE; MYOSIN HEAVY CHAIN; POLYAMIDE; TENASCIN; TRANSGELIN; NYLON;

ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; ENDOMETRIAL MESENCHYMAL STEM CELL; ENDOMETRIUM CELL; FASCIA; FEMALE; FIBROBLAST; GELATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IN VIVO STUDY; MESENCHYMAL STEM CELL; MTS ASSAY; PELVIC ORGAN PROLAPSE; PHENOTYPE; PRIORITY JOURNAL; REOPERATION; SMOOTH MUSCLE FIBER; SURGICAL MESH; TISSUE ENGINEERING; TISSUE SCAFFOLD; BATCH CELL CULTURE; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DEVICE FAILURE ANALYSIS; DEVICES; ENDOMETRIUM; EQUIPMENT DESIGN; MATERIALS TESTING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PHYSIOLOGY; PROCEDURES; SOFT TISSUE INJURY; SURGERY;

BATCH CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENDOMETRIUM; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FASCIA; FEMALE; GELATIN; HUMANS; MATERIALS TESTING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NYLONS; SOFT TISSUE INJURIES; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84925344581     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.08.031     Document Type: Article

References (47)

1. Haylen BT, De Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4-20.
2. Hendrix SL, Clark A, Nygaard I, Aragaki A, Barnabei V, McTiernan A. Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol 2002; 186: 1160-6.
3. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89: 501-6.
4. Smith FJ, Holman CDJ, Moorin RE, Tsokos N. Lifetime risk of undergoing surgery for pelvic organ prolapse. Obstet Gynecol 2010; 116: 1096-100.
5. DeLancey JOL, Kane Low L, Miller JM, Patel DA, Tumbarello JA. Graphic integration of causal factors of pelvic floor disorders: an integrated life span model. Am J Obstet Gynecol 2008; 199(610): e1-5.
6. Altman D, Väyrynen T, Engh ME, Axelsen S, Falconer C. Short-term outcome after transvaginal mesh repair of pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 787-93.
7. Migliari R, De Angelis M, Pistolesi D. The use of synthetic mesh in pelvic floor defect repair. Urodinamica 2003; 13: 81-91.
8. Babensee JE, Anderson JM, McIntire LV, Mikos AG. Host response to tissue engineered devices. Adv Drug Deliv Rev 1998; 33: 111-39.
9. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol 2008; 20: 86-100.
10. FDA Public Health Notification: serious complications associated with transvaginal placement of surgical mesh in repair of pelvic organ prolapse and stress urinary incontinence. 2008.
11. FDA Safety Communication: update on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse. Date issued: July 13, 2011.
12. Lim YN, Muller R, Corstiaans A, Hitchins S, Barry C, Rane A. A long-term review of posterior colporrhaphy with Vypro 2 mesh. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 1053-7.
13. Ho MH, Heydarkhan S, Vernet D, Kovanecz I, Ferrini MG, Bhatia NN, et al. Stimulating vaginal repair in rats through skeletal muscle-derived stem cells seeded on small intestinal submucosal scaffolds. Obstet Gynecol 2009; 114: 300-9.
14. Dolce CJ, Stefanidis D, Keller JE, Walters KC, Newcomb WL, Heath JJ, et al. Pushing the envelope in biomaterial research: initial results of prosthetic coating with stem cells in a rat model. Surg Endosc 2010; 24: 2687-93.
15. Schwab KE, Gargett CE. Co-expression of two perivascular cell markers isolates mesenchymal stem-like cells from human endometrium. Hum Reprod 2007; 22: 2903-11.
16. Masuda H, Anwar SS, B?hring H, Rao JR, Gargett CE. A novel marker of human endometrial mesenchymal stem-like cells. Cell Transplant 2012; 21: 2201-14.
17. Ulrich D, Muralitharan R, Gargett CE. Toward the use of endometrial and menstrual blood mesenchymal stem cells for cell-based therapies. Expert Opin Biol Ther 2013; 13: 1387-400.
18. Rajaraman G, White J, Tan KS, Ulrich D, Rosamilia A, Werkmeister J, et al. Optimization and scale-up culture of human endometrial multipotent mesenchymal stromal cells: potential for clinical application. Tissue Eng Part C Methods 2013; 19: 80-92.
19. Edwards SL, Werkmeister JA, Rosamilia A, Ramshaw JAM, White JF, Gargett CE. Characterisation of clinical and newly fabricated meshes for pelvic organ prolapse repair. J Mech Behav Biomed Mater 2013; 23: 53-61.
20. Ulrich D, Edwards SL, White JF, Supit T, Ramshaw JAM, Lo C, et al. A preclinical evaluation of alternative synthetic biomaterials for fascial defect repair using a rat abdominal hernia model. PLoS One 2012; 7: 10.
21. Ulrich D, Edwards SL, Su K, Tan KS, White JF, Ramshaw JAM, et al. Human endometrial mesenchymal stem cells modulate the tissue response and mechanical behavior of polyamide mesh implants for pelvic organ prolapse repair. Tissue Eng Part A 2014; 20: 785-98.
22. Lai JY, Lin PK, Hsiue GH, Cheng HY, Huang SJ, Li YT. Low bloom strength gelatin as a carrier for potential use in retinal sheet encapsulation and transplantation. Biomacromolecules 2009; 10: 310-9.
23. Van Luyn MJA, Van Wachem PB, Damink LO, Dijkstra PJ, Feijen J, Nieuwenhuis P. Relations between in vitro cytotoxicity and crosslinked dermal sheep collagens. J Biomed Mater Res 1992; 26: 1091-110.
24. Gong Y, Su K, Lau TT, Zhou R, Wang DA. Microcavitary hydrogel-mediating phase transfer cell culture for cartilage tissue engineering. Tissue Eng Part A 2010; 16: 3611-22.
25. Ross JJ, Hong Z, Willenbring B, Zeng L, Isenberg B, Eu HL, et al. Cytokineinduced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. J Clin Invest 2006; 116: 3139-49.
26. Werkmeister JA, Ramshaw JAM, Ellender G. Characterisation of a monoclonal antibody against native human type I collagen. Eur J Biochem 1990; 187: 439-43.
27. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62-4.
28. Mangera A, Bullock AJ, Chapple CR, MacNeil S. Are biomechanical properties predictive of the success of prostheses used in stress urinary incontinence and pelvic organ prolapse? A systematic review. Neurourol Urodyn 2012; 31: 13-21.
29. Mangera A, Bullock AJ, Roman S, Chapple CR, Macneil S. Comparison of candidate scaffolds for tissue engineering for stress urinary incontinence and pelvic organ prolapse repair. BJU Int 2013; 112: 674-85.
30. Roman S, Mangera A, Osman NI, Bullock AJ, Chapple CR, Macneil S. Developing a tissue engineered repair material for treatment of stress urinary incontinence and pelvic organ prolapse - which cell source? Neurourol Urodyn 2014; 33: 531-7.
31. Long JL, Tranquillo RT. Elastic fiber production in cardiovascular tissueequivalents. Matrix Biol 2003; 22: 339-50.
32. L'Heureux N, P?quet S, Labbé R, Germain L, Auger FA. A completely biological tissue-engineered human blood vessel. FASEB J 1998; 12: 47-56.
33. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.
34. Miano JM. Mammalian smooth muscle differentiation: origins, markers and transcriptional control. Results Probl Cell Differ 2002; 38: 39-59.
35. Sinha S, Hoofnagle MH, Kingston PA, McCanna ME, Owens GK. Transforming growth factor-b1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol 2004; 287: C1560-8.
36. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-?2 in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999; 126: 3047-55.
37. Dandre F, Owens GK. Platelet-derived growth factor-BB and Ets-1 transcription factor negatively regulate transcription of multiple smooth muscle cell differentiation marker genes. Am J Physiol Heart Circ Physiol 2004; 286: H2042-51.
38. Rodr?guez LV, Alfonso Z, Zhang R, Leung J, Wu B, Ignarro LJ. Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cells. Proc Natl Acad Sci USA 2006; 103: 12167-72.
39. Wolf NS, Penn PE, Rao D, McKee MD. Intraclonal plasticity for bone, smooth muscle, and adipocyte lineages in bone marrow stroma fibroblastoid cells. Exp Cell Res 2003; 290: 346-57.
40. Religa P, Bojakowski K, Maksymowicz M, Bojakowska M, Sirsjo A, Gaciong Z, et al. Smooth-muscle progenitor cells of bone marrow origin contribute to the development of neointimal thickenings in rat aortic allografts and injured rat carotid arteries. Transplantation 2002; 74: 1310-5.
41. Gargett CE, Masuda H. Adult stem cells in the endometrium. Mol Hum Reprod 2010; 16: 818-34.
42. Yang Y, Relan NK, Przywara DA, Schuger L. Embryonic mesenchymal cells share the potential for smooth muscle differentiation: myogenesis is controlled by the cell's shape. Development 1999; 126: 3027-33.
43. Lee CH, Moioli EK, Mao JJ. Fibroblastic differentiation of human mesenchymal stem cells using connective tissue growth factor. Annu Int Conf IEEE Eng Med Biol Proc 2006; 4030285: 775-8.
44. Grotendorst GR, Rahmanie H, Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J 2004; 18: 469-79.
45. Suzuki T, Kim HS, Kurabayashi M, Hamada H, Fujii H, Aikawa M, et al. Preferential differentiation of P19 mouse embryonal carcinoma cells into smooth muscle cells: use of retinoic acid and antisense against the central nervous system-specific POU transcription factor Brn-2. Circ Res 1996; 78: 395-404.
46. Eghbali M, Tomek R, Woods C, Bhambi B. Cardiac fibroblasts are predisposed to convert into myocyte phenotype: specific effect of transforming growth factor b. Proc Natl Acad Sci USA 1991; 88: 795-9.
47. Xie C, Ritchie RP, Huang H, Zhang J, Chen YE. Smooth muscle cell differentiation in vitro: models and underlying molecular mechanisms. Arterioscler Thromb Vasc Biol 2011; 31: 1485-94.